They also confirmed that fenofibrate (145 mg) prevents TG elevations in the setting of combination therapy with firsocostat and the farnesoid X receptor agonist, cilofexor, in hypertriglyceridemic patients with NASH (13). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.